TY - JOUR
T1 - Satisfaction and attitudes toward systemic treatments for psoriasis
T2 - A cross-sectional study
AU - Esposito, Maria
AU - Giunta, Alessandro
AU - Gisondi, Paolo
AU - Tambone, Sara
AU - Rovaris, Marco
AU - Manfreda, Valeria
AU - Pirro, Federico
AU - Pellegrini, Cristina
AU - Fargnoli, Maria Concetta
AU - Bianchi, Luca
AU - Peris, Ketty
AU - Girolomoni, Giampiero
N1 - Funding Information:
Maria Esposito has served as speaker and/or consultant for Abbvie, Almirall, Biogen, Celgene, Eli Lilly, Janssen, Leo Pharma, Novartis, Sanofi Genzyme, UCB. Alessandro Giunta has served has speaker and/or consultant for Abbvie, Biogen, Eli Lilly, Pfizer, UCB. Paolo Gisondi has been a consultant and/or speaker for Abbvie, Almirall, Celgene, Janssen, Leo-pharma, Eli Lilly, Merck Sharp & Dohme, Novartis, Pfizer, Sandoz, UCB. Maria Concetta Fargnoli has served on advisory boards, received honoraria for lectures and research grants from Almirall, Abbvie, Galderma, Leo Pharma, Mylan, Medac Pharma, Celgene, Pierre Fabre, UCB, Eli Lilly, Pfizer, Janssen, Novartis, Sanofi-Genzyme, Roche, Sunpharma, and MSD. Luca Bianchi has served as consultant and speaker for Abbvie, Janssen, Pfizer and Novartis. Ketty Peris reports grants and personal fees from Almirall and AbbVie, and personal fees from Biogen, Lilly, Celgene, Galderma, Leo Pharma, Novartis, Pierre Fabre, Sanofi, Sandoz, Sun Pharma and Janssen, outside the submitted work. Giampiero Girolomoni has been principal investigator in clinical trials sponsored by and/or and has received personal fees from AbbVie, Abiogen, Almirall, Alphasights, Amgen, Biogen, Bristol-Meyers Squibb, Celgene, Celltrion, Eli-Lilly, Genzyme, Gerson Lehrman Group, Guidepoint Global, Leo Pharma, Menlo therapeutics, Novartis, OM Pharma, Pfizer, Regeneron, Samsung, Sandoz and UCB.
Funding Information:
Maria Esposito has served as speaker and/or consultant for Abbvie, Almirall, Biogen, Celgene, Eli Lilly, Janssen, Leo Pharma, Novartis, Sanofi Genzyme, UCB. Alessandro Giunta has served has speaker and/or consultant for Abbvie, Biogen, Eli Lilly, Pfizer, UCB. Paolo Gisondi has been a consultant and/or speaker for Abbvie, Almirall, Celgene, Janssen, Leo‐pharma, Eli Lilly, Merck Sharp & Dohme, Novartis, Pfizer, Sandoz, UCB. Maria Concetta Fargnoli has served on advisory boards, received honoraria for lectures and research grants from Almirall, Abbvie, Galderma, Leo Pharma, Mylan, Medac Pharma, Celgene, Pierre Fabre, UCB, Eli Lilly, Pfizer, Janssen, Novartis, Sanofi‐Genzyme, Roche, Sunpharma, and MSD. Luca Bianchi has served as consultant and speaker for Abbvie, Janssen, Pfizer and Novartis. Ketty Peris reports grants and personal fees from Almirall and AbbVie, and personal fees from Biogen, Lilly, Celgene, Galderma, Leo Pharma, Novartis, Pierre Fabre, Sanofi, Sandoz, Sun Pharma and Janssen, outside the submitted work. Giampiero Girolomoni has been principal investigator in clinical trials sponsored by and/or and has received personal fees from AbbVie, Abiogen, Almirall, Alphasights, Amgen, Biogen, Bristol‐Meyers Squibb, Celgene, Celltrion, Eli‐Lilly, Genzyme, Gerson Lehrman Group, Guidepoint Global, Leo Pharma, Menlo therapeutics, Novartis, OM Pharma, Pfizer, Regeneron, Samsung, Sandoz and UCB.
Publisher Copyright:
© 2021 The Authors. Dermatologic Therapy published by Wiley Periodicals LLC.
PY - 2021/5/1
Y1 - 2021/5/1
N2 - In psoriasis patients, satisfaction and patients' attitude toward treatment are heterogeneous depending on several factors and remain poorly investigated, although the availability of several new targeted therapeutic options. A multicentre cross-sectional investigation was conducted to estimate treatment satisfaction and attitudes (awareness, trust, and therapeutic alliance) in a large population of adult psoriasis patients undergoing a systemic biologic or non-biologic agent for moderate-to-severe plaque-type psoriasis. Patients' satisfaction was measured using the Treatment Satisfaction Questionnaire for Medication II questionnaire and patients' attitudes toward treatment were evaluated using a Lickert scale. Results were related to patients' and treatment characteristics and therapeutic outcomes. The study included 899 psoriasis patients and demonstrated high-treatment satisfaction and positive attitudes toward systemic treatments, with greater influence of the perceived efficacy and the type of treatment. Biologic treatments and, in particular anti-IL17 agents showed higher results. More efforts in developing tools facilitating communication and exploring important aspects of patients' view are needed.
AB - In psoriasis patients, satisfaction and patients' attitude toward treatment are heterogeneous depending on several factors and remain poorly investigated, although the availability of several new targeted therapeutic options. A multicentre cross-sectional investigation was conducted to estimate treatment satisfaction and attitudes (awareness, trust, and therapeutic alliance) in a large population of adult psoriasis patients undergoing a systemic biologic or non-biologic agent for moderate-to-severe plaque-type psoriasis. Patients' satisfaction was measured using the Treatment Satisfaction Questionnaire for Medication II questionnaire and patients' attitudes toward treatment were evaluated using a Lickert scale. Results were related to patients' and treatment characteristics and therapeutic outcomes. The study included 899 psoriasis patients and demonstrated high-treatment satisfaction and positive attitudes toward systemic treatments, with greater influence of the perceived efficacy and the type of treatment. Biologic treatments and, in particular anti-IL17 agents showed higher results. More efforts in developing tools facilitating communication and exploring important aspects of patients' view are needed.
KW - biologics
KW - patients' attitudes
KW - psoriasis
KW - treatment satisfaction
UR - http://www.scopus.com/inward/record.url?scp=85103169634&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85103169634&partnerID=8YFLogxK
U2 - 10.1111/dth.14949
DO - 10.1111/dth.14949
M3 - Article
C2 - 33724607
AN - SCOPUS:85103169634
VL - 34
JO - Dermatologic Therapy
JF - Dermatologic Therapy
SN - 1396-0296
IS - 3
M1 - e14949
ER -